Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, Clinical Pathways, begins this next segment from a different perspective.
Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, Clinical Pathways, begins this next segment from a different perspective.
He begins by discussing how a large aging population means that the incidence of cancer is rising. With that influx comes complexity and greater chronicity. To care for this requires innovation, but with that innovation comes cost.
He suggests that organizations like Cardinal Health provide one example of how organizations are successfully navigating clinical pathways. Several things set them apart from the competition, including interactive technology and “behavioral economics of medicine.” He says that reluctance in adopting effective models in clinical pathways is a “culture of medicine” issue: “I would argue that this is not necessarily a performance issue that’s related to value versus volume, it’s not a reimbursement problem, and I’m not convinced it’s an evidence problem. What I do believe, it’s a cultural problem, and our culture of medicine impacts our doctors and it impacts our patients, and if we don't get to the culture of medicine issue, then we’re really ignoring the elephant in the room. It’s a culture of medicine which embraces now over later, new over old, and more over less.”
In order to be an effective leader such as Cardinal Health, Dr Feinberg says that organizations should focus on behaviors with the greatest impact on cost and quality, engage physicians intensively, provide patient education in real time, and provide the health information technology solutions that allow providers to engage with patients in real time.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More